Analyst Rating
based on 4 analysts
75.00%
Buy
0.00%
Hold
25.00%
Sell
Based on 4 analysts offering long term price targets for Strides Pharma Science Ltd. An average target of ₹1208.25
Source: S&P Global Market Intelligence
Strides Pharma Science Ltd Share analysis
Strides Pharma Science Ltd price forecast by 4 analysts
Downside of
High
₹1348
Target
₹1208.25
Low
₹1110
Strides Pharma Science Ltd target price ₹1208.25, a slight downside of -11.53% compared to current price of ₹1328. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Strides Pharma Science Ltd revenue growth forecast
Expected growth rate Q1, FY2026:26.91%
Forecast
Actual
Including amortisation and stock based compensations
Strides Pharma Science Ltd EPS growth forecast
EPS estimate Q1, FY2026:
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,315.15₹1,382.8552 Week's Low
52 Week's High
₹467₹1,431
| Returns % | |
| 1 Month Return | + 7.06 % |
| 3 Month Return | + 42.74 % |
| 1 Year Return | + 179.83 % |
| Market Stats | |
| Previous Close | ₹1,365.70 |
| Open | ₹1,365.70 |
| Volume | 2.80L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹12,558.73Cr |
Key Statistics
| P/E Ratio | 2677.84 |
| PEG Ratio | 308.51 |
| Market Cap | ₹12,558.73 Cr |
| P/B Ratio | 2.02 |
| EPS | -10.26 |
| Dividend Yield | 0.32 |
| Sector | Pharmaceuticals |
| ROE | 1.87 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹12,558.73 Cr | 55.97% | 0.66 | -₹95 Cr | ₹4,051 Cr | |
| NA | ₹1,690.10 Cr | 487.73% | 0.54 | ₹30 Cr | ₹227 Cr | |
| BUY | ₹12,743.87 Cr | 377.48% | 0.51 | ₹314 Cr | ₹2,177 Cr | |
| NA | ₹190.28 Cr | 106.75% | 0.73 | NA | NA | |
| NA | ₹376.46 Cr | 9.34% | 0.00 | NA | NA |
Mutual Fund Holdings
Company Information
Share Price: ₹1328.00 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹12,558.73Cr as of today
Revenue: ₹1,087.51Cr as on June 2024 (Q2 24)
Net Profit: ₹68.31Cr as on June 2024 (Q2 24)
Listing date: 02 Feb, 2000
Chairperson Name: Arun Kumar
| Organisation | Strides Pharma Science Ltd |
| Headquarters | Bangaluru |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Strides Pharma Science Ltd
Strides Pharma Secures FDA Approval for Fluoxetine - 17 Sep, 2024
Strides Pharma's subsidiary, Strides Pharma Global Pte. Ltd., has received US FDA approval for its generic Fluoxetine tablets (60 mg), to be produced at its Puducherry facility.
Strides Pharma Gains FDA Approval and Analyst Upgrade - 16 Sep, 2024
Strides Pharma Science received USFDA approval for Fluoxetine 60 mg tablets, enhancing its product range. Axis Direct issued a buy rating with a target of Rs 1,550. Following the news, shares surged to an all-time high.
Aditya Birla Reduces Stake in Strides Pharma - 13 Sep, 2024
Aditya Birla Sun Life Mutual Fund has decreased its stake in Strides Pharma Science Ltd to 3.49%, down from 5.55%. Despite this reduction, Strides Pharma's share price has shown strong performance, rising 190.68% over the past year.
Strides Pharma Secures Approval for OneSource CDMO - 11 Sep, 2024
Strides Pharma Science has received overwhelming approval from shareholders and creditors to create OneSource, India's first specialty pharma CDMO, integrating various advanced sectors. This strategic initiative aims to unlock significant value for stakeholders upon listing.
Strides Pharma Declares Dividend Amid Business Consolidation - 09 Sep, 2024
Strides Pharma Science declared a final dividend of Rs 2.50 per share. Proxy advisory firms recommend voting against a business consolidation proposal involving Strides and affiliates.
Strides Pharma Secures USFDA Approval for Asthma Drug - 06 Sep, 2024
Strides Pharma Science's subsidiary received USFDA approval for generic Theophylline extended-release tablets, leading to a surge in stock price and market confidence. The product has a combined market size of $11.5 million.
Strides Pharma Receives FDA Report for Chennai Facility - 19 Aug, 2024
Strides Pharma's subsidiary, Strides Alathur, received an Establishment Inspection Report from the USFDA, confirming a successful GMP inspection with a Voluntary Action Indicated classification. The facility is crucial for producing tablets and capsules for the US market.
Insights on Strides Pharma Science Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 1.07K Cr → 1.10K Cr (in ₹), with an average increase of 2.7% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 24.57% to 26.71% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 18.18 Cr → 70.2 Cr (in ₹), with an average increase of 74.1% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, STAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 1 year, STAR stock has moved up by 179.8%
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 9.4%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 10.57% to 10.50% in Jun 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 25.88% to 25.86% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 31.50% to 28.87% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 25.86% | ||
| Foreign Institutions | 26.71% | 8.69 | |
| Mutual Funds | 10.5% | ||
| Retail Investors | 28.87% | ||
| Others | 8.06% | 7.78 |
Key Indicators
Strides Pharma Science Ltd Valuation
Strides Pharma Science Ltd in the last 5 years
Lowest (-179.24x)
July 5, 2021
Industry (58.50x)
September 18, 2024
Today (2677.84x)
September 18, 2024
Highest (2736.18x)
September 16, 2024
Earnings and Dividends
Strides Pharma Science Ltd Earnings Results
Strides Pharma Science Ltd’s net profit jumped 1087.34% since last year same period to ₹70.20Cr in the Q1 2024-2025. On a quarterly growth basis, Strides Pharma Science Ltd has generated 286.14% jump in its net profits since last 3-months.
Read More about Earnings ResultsStrides Pharma Science Ltd Dividends May,2024
In the quarter ending March 2024, Strides Pharma Science Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.29%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Strides Pharma Science Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Strides Pharma Science Ltd shares.
Strides Pharma Science Ltd (STAR) share price today is ₹1328
Strides Pharma Science Ltd is listed on NSE
Strides Pharma Science Ltd is listed on BSE
- Today’s highest price of Strides Pharma Science Ltd is ₹1382.85.
- Today’s lowest price of Strides Pharma Science Ltd is ₹1315.15.
PE Ratio of Strides Pharma Science Ltd is 2677.84
PE ratio = Strides Pharma Science Ltd Market price per share / Strides Pharma Science Ltd Earnings per share
Today’s traded volume of Strides Pharma Science Ltd(STAR) is 2.80L.
Today’s market capitalisation of Strides Pharma Science Ltd(STAR) is ₹12558.73Cr.
| Strides Pharma Science Ltd(STAR | Price |
|---|---|
52 Week High | ₹1431 |
52 Week Low | ₹467 |
Strides Pharma Science Ltd(STAR) share price is ₹1328. It is down -7.20% from its 52 Week High price of ₹1431
Strides Pharma Science Ltd(STAR) share price is ₹1328. It is up 184.37% from its 52 Week Low price of ₹467
| Strides Pharma Science Ltd(STAR | Returns |
|---|---|
1 Day Returns | -37.7% |
1 Month Returns | 7.06% |
3 Month Returns | 42.74% |
1 Year Returns | 179.83% |